Oxcarbazepine Tablet, Film Coated
Product Images NDC 62756-185

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Oxcarbazepine (NDC 62756-185). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical structure of Oxcarbazepine, a human prescription drug. The diagram shows the molecular framework including two benzene rings, a ketone group, a nitrogen atom bonded to an amide group, representing the active ingredient Oxcarbazepine.*

FDA Label Image

Figure 1 (Figure1)

A Kaplan-Meier plot depicting exit rates over time in days for two treatment groups: Oxcarbazepine and placebo. The y-axis shows the exit rate from 0 to 1, and the x-axis represents time on trial from day 2 to day 11. The plot includes a log-rank test p-value of 0.0001, indicating statistical analysis of differences between the groups.*

FDA Label Image

Figure-2 (Figure2)

A Kaplan-Meier curve showing estimates of first seizure event rates over time comparing two treatment groups: Oxcarbazepine and Placebo. The x-axis represents days from first dose to first seizure, and the y-axis represents the seizure rate. The graph includes a log-rank test p-value of 0.046 indicating statistical comparison between groups.*

FDA Label Image

Figure-3 (Figure3)

Kaplan-Meier plot showing exit rate over time (days) for two treatment groups labeled HIGH and LOW. The vertical axis represents exit rate from 0 to 1.0, and the horizontal axis represents time to exit in days from 0 to 130. The plot includes a log-rank test p-value of 0.0001 indicating statistical comparison between groups.*

FDA Label Image

Figure-4 (Figure4)

A Kaplan-Meier estimate graph showing exit rates over time (days) comparing two treatment groups labeled High and Low. The y-axis represents exit rate, while the x-axis shows time to exit in days. The graph includes a log-rank test p-value of 0.0001 indicating statistical comparison of the groups.*

FDA Label Image

Spl-oxcarbazepine-label-1 (Spl Oxcarbazepine Label 1)

Oxcarbazepine 150 mg film-coated tablets label displaying NDC 62756-183-83. The label states the strength as 150 mg and the package count as 30 tablets. Manufactured by Sun Pharmaceutical Industries Limited in Gujarat, India, and distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ. Storage instructions and pharmacist dispensing information are also included.*

FDA Label Image

Spl-oxcarbazepine-label-2 (Spl Oxcarbazepine Label 2)

Label for Oxcarbazepine Tablets 300 mg oral film-coated tablets. The label states each tablet contains 300 mg oxcarbazepine USP, with a package size of 30 tablets. It is manufactured by Sun Pharmaceutical Industries Limited and distributed by Sun Pharmaceutical Industries, Inc. The label includes storage instructions and a pharmacist dispensing notice.*

FDA Label Image

Spl-oxcarbazepine-label-3 (Spl Oxcarbazepine Label 3)

Oxcarbazepine Tablets 600 mg film-coated oral tablets, packaged in a container of 30 tablets. Label from Sun Pharmaceutical Industries, Inc., with storage instructions and dispensing information. The label includes the NDC 62756-185-83 and directions for pharmacists to provide a medication guide to each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.